Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28.5M
-
Number of holders
-
30
-
Total 13F shares, excl. options
-
3.9M
-
Shares change
-
+124K
-
Total reported value, excl. options
-
$20.3M
-
Value change
-
+$545K
-
Number of buys
-
19
-
Number of sells
-
-7
-
Price
-
$5.19
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q2 2017
35 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q2 2017.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.9M shares
of 28.5M outstanding shares and own 13.69% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (3.06M shares), BlackRock Inc. (198K shares), Artal Group S.A. (150K shares), BRIDGEWAY CAPITAL MANAGEMENT INC (145K shares), VANGUARD GROUP INC (109K shares), GOLDMAN SACHS GROUP INC (42K shares), NORTHERN TRUST CORP (40.7K shares), Destination Wealth Management (29.7K shares), Family Management Corp (22.6K shares), and GEODE CAPITAL MANAGEMENT, LLC (21.5K shares).
This table shows the top 30 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.